Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Duration: June 1, 2021
to
present
General Issues: Health Issues
Spending: about $480,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2021: House of Representatives, U.S. Senate
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Keenan Austin Reed Chief of Staff, Rep. Donald McEachin; Deputy Chief of Staff, Rep. Frederica S. Wilson
Courtney Johnson Research Assistant, House Energy & Commerce Committee
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2024
In Q1, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on April 22.
Original Filing: 301576678.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2023
In Q4, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Jan. 22.
Original Filing: 301540643.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2023
In Q3, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $50,000. The report was filed on Oct. 19, 2023.
Original Filing: 301508913.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2023
In Q2, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on July 18, 2023.
Original Filing: 301479663.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2023
In Q1, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on April 20, 2023.
Original Filing: 301468084.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health;
Proposals related to drug pricing, drug price transparency, PBMS;
Discussions on value-based contracting
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
Implementation of the Inflation Reduction Act;
Reauthorization of the Pandemic All Hazards Preparedness Act
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2022
In Q4, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439377.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
The Prescription Drug User Fee Act reauthorization
Inflation Reduction Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 14, 2022.
Original Filing: 301404447.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Issues related to plasma derived therapies;
The Prescription Drug User Fee Act reauthorization
Inflation Reduction Act
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on July 20, 2022.
Original Filing: 301396045.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
HR 5376, the Build Back Better Act
Issues related to plasma derived therapies;
The Prescription Drug User Fee Act reauthorization
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on April 20, 2022.
Original Filing: 301372405.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
HR 5376, the Build Back Better Act
Issues related to plasma derived therapies;
The Prescription Drug User Fee Act reauthorization
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2021
In Q4, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Jan. 18, 2022.
Original Filing: 301325563.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
HR 5376, the Build Back Better Act
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $40,000. The report was filed on Oct. 19, 2021.
Original Filing: 301305454.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, ALPINE GROUP PARTNERS, LLC. lobbied for Takeda Pharmaceuticals America, Inc. , earning $10,000. The report was filed on July 20, 2021.
Original Filing: 301291622.xml
Lobbying Issues
Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883 To amend part D of title XVIII of the Social Security Act to require the Secretary of Health and Human Services to negotiate converted part D drug prices on behalf of Medicare beneficiaries - provisions related to Part D and drug-pricing negotiation
S. 2543 The Prescription Drug Pricing Reduction Act of 2019 (116th Congress)- provisions related to the AMP cap removal, Medicare Par D redesign, exclusivity periods, vial wastage, drug price transparency, add -on payments and pay-fors;
H.R.1319, P.L. 117-2, American Rescue Plan Act of 2021 - provisions related to COVID-19 vaccinations, testing, treatment, Medicaid rebates, and prevention and mental health services;
E.O. 13937, Access to Affordable Life-Saving Medications;
E.O. 13938, Increasing Drug Importation to Lower Prices for American Patients;
E.O. 13939, Lowering Drug Prices by Eliminating Kickbacks to Middlemen;
E.O. 13947, 13948, Lowering Drug Prices by Putting America First;
E.O. 13944, Combating Public Health Emergencies and Strengthening National Security by Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs are Made in the United States;
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
ALPINE GROUP PARTNERS, LLC. filed a lobbying registration on July 19, 2021 to represent Takeda Pharmaceuticals America, Inc., effective June 1, 2021.
Original Filing: 301279977.xml
Issue(s) they said they’d lobby about: Proposals related to health equity, including but not limited to: clinical trial diversity, issues of patient assistance programs, and social determinants of health; and
Proposals related to drug pricing, including House and Senate draft bills
Issues related to the use of plasma therapies in COVID-19 patient;
Discussions on value-based contracting
H.4. 2017, S. 883
S. 2543
H.R.1319, P.L. 117-2
E.O. 13937, 13938, 13939, 13947, 13948, 13944 .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...